ArticleThe Lancet regional health. Western Pacific2026
Airway clearance management for bronchiectasis in China: a multicentre cross-sectional study from the Chinese bronchiectasis registry (BE-China).
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Airway clearance techniques (ACTs) are guideline-recommended in bronchiectasis, while contemporary patterns and determinants of ACTs adoption remain unclear in China. Methods: A multicentre cross-sectional study was conducted using data from the BE-China cohort between 10 Jan 2020 and 31 Mar 2024. Clinical characteristics and prespecified ACT modalities were collected across 92 hospitals. Multivariable logistic regression identified important associations of ACTs utilization. Findings: Among 9647 patients, 12.2% (1177) used regular ACTs at baseline, and regional heterogeneity in ACTs utilization was observed. Moreover, ACTs users exhibited prolonged disease duration, a higher proportion of severe disease, greater comorbidity, heavier cough and sputum burden, and more frequent pharmacological and ventilatory interventions. Variables associated with increased ACTs utilization included comorbid burden (OR 1.47, 1.28-1.70; p < 0.0001), daily sputum (OR 1.68, 1.33-2.10; p < 0.0001), expectorants usage (OR 3.19, 2.74-3.71; p < 0.0001), inhaled antibiotics (OR 2.04, 1.35-3.07; p = 0.00065), macrolide therapy (OR 2.31, 1.78-2.99; p < 0.0001), other long-term oral antibiotics (OR 1.37, 1.13-1.66; p = 0.0013), noninvasive ventilation requirement (OR 4.11, 3.14-5.39; p < 0.0001), and disease duration (per SD increase, OR 1.08, 1.01-1.15; p = 0.027). Both BE-China and the similar European Bronchiectasis Registry (EMBARC) cohorts showed distinct etiological and comorbidity profiles, yet consistently revealed a higher medication burden among ACTs users. Interpretation: In China, ACTs utilization is primarily concentrated among patients with bronchiectasis who have a heavier symptom burden and greater treatment intensity. Clinicians may leverage the identified associations to optimize adherence and guide phenotype-targeted ACTs implementation strategies, and these findings may serve as a reference for future research. Funding: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Innovation Program of Shanghai Municipal Education Commission, Program of Shanghai Municipal Science and Technology Commission, Major Project of Guangzhou National Laboratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.